Status:
WITHDRAWN
A Study Of Tasocitinib In Dry Eye Subjects
Lead Sponsor:
Pfizer
Conditions:
Keratoconjunctivitis Sicca
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease. Both subjective and objective clinical endpoint...
Eligibility Criteria
Inclusion
- Males and females aged 18 years or older at time of consent
- Diagnosis of dry eye disease, characterized by subjective symptoms of dry eye for at least 6 months, Schirmer test without anesthesia: =\>1 mm and =\<7 mm, sum of corneal fluorescein staining score of =\>4 (NEI Scale), and subject grading total score of =\> 23 on the OSDI
Exclusion
- Planned initiation of, or changes to, concomitant medication that could affect dry eye within 30 days of the Screening visit or during study
- Ocular disorders that may confound interpretation of study results such as significant corneal surface disease not caused by dry eyes, abnormal corneal sensitivity, abnormal tear spreading, including but not limited to the following: abnormal lid function, lid position, or blink rate, that in the opinion of the investigator is clinically significant, history of herpetic keratopathy
- Lacrimal punctal occlusion (plugs or cautery) within 2 months of the Screening visit
- Contact lens wear within 2 weeks of the Screening visit and/or during study participation.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01226680
Start Date
December 1 2010
End Date
October 19 2012
Last Update
November 29 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.